Mazor Robotics (MZOR) Raised to “Hold” at Vetr
Mazor Robotics (NASDAQ:MZOR) was upgraded by equities research analysts at Vetr from a “sell” rating to a “hold” rating in a report released on Monday. The firm presently has a $74.27 target price on the medical instruments supplier’s stock. Vetr‘s price target indicates a potential upside of 2.06% from the stock’s previous close.
MZOR has been the topic of several other research reports. BidaskClub lowered shares of Mazor Robotics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 2nd. Zacks Investment Research lowered shares of Mazor Robotics from a “buy” rating to a “hold” rating in a research report on Saturday, January 13th. Barclays reaffirmed a “sell” rating and set a $36.00 price target on shares of Mazor Robotics in a research report on Tuesday, January 9th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Mazor Robotics in a research report on Wednesday, February 14th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $48.75.
Mazor Robotics (MZOR) opened at $72.77 on Monday. The firm has a market capitalization of $1,990.00, a P/E ratio of -142.69 and a beta of 1.18. Mazor Robotics has a twelve month low of $22.44 and a twelve month high of $76.56.
Hedge funds have recently added to or reduced their stakes in the company. AlphaStar Capital Management LLC purchased a new stake in shares of Mazor Robotics during the 3rd quarter valued at approximately $414,000. Dorsey Wright & Associates purchased a new stake in Mazor Robotics in the third quarter valued at approximately $4,537,000. Global X MANAGEMENT CO LLC raised its position in Mazor Robotics by 5,758.8% in the third quarter. Global X MANAGEMENT CO LLC now owns 115,536 shares of the medical instruments supplier’s stock valued at $5,704,000 after purchasing an additional 113,564 shares during the period. EAM Investors LLC raised its position in Mazor Robotics by 68.2% in the third quarter. EAM Investors LLC now owns 119,083 shares of the medical instruments supplier’s stock valued at $5,879,000 after purchasing an additional 48,299 shares during the period. Finally, Fagan Associates Inc. raised its position in Mazor Robotics by 22.2% in the third quarter. Fagan Associates Inc. now owns 26,200 shares of the medical instruments supplier’s stock valued at $1,293,000 after purchasing an additional 4,760 shares during the period. 24.09% of the stock is currently owned by hedge funds and other institutional investors.
About Mazor Robotics
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include Renaissance Guidance System, which can improve the execution and outcomes in a wide variety of procedures, including percutaneous degenerative repair, pedicle screw fixation for complex spinal deformity, and vertebral augmentation; Mazor X, the Surgical Assurance Platform for Spine Surgery.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Mazor Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics and related companies with MarketBeat.com's FREE daily email newsletter.